Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century

Authors :: Ngabonziza, Jean Claude S.
Rigouts, Leen
Torrea, Gabriela
Decroo, Tom
Kamanzi, Eliane
Lempens, Pauline
Rucogoza, Aniceth
Habimana, Yves M.
Laenen, Lies
Niyigena, Belamo E.
Uwizeye, Cécile
Ushizimpumu, Bertin
Mulders, Wim
Ivan, Emil
Tzfadia, Oren
Muvunyi, Claude Mambo
Migambi, Patrick
Andre, Emmanuel
Mazarati, Jean Baptiste
Affolabi, Dissou
Umubyeyi, Alaine N.
Nsanzimana, Sabin
Portaels, Françoise
Gasana, Michel
de Jong, Bouke C.
Meehan, Conor J.
Source :: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases; May 2022, Vol. 27 Issue: 1
Publication Year :: 2022
Abstract: Multidrug-resistant (MDR) tuberculosis (TB) poses an important challenge in TB management and control. Rifampicin resistance (RR) is a solid surrogate marker of MDR-TB. We investigated the RR-TB clustering rates, bacterial population dynamics to infer transmission dynamics, and the impact of changes to patient management on these dynamics over 27 years in Rwanda.

Language :: English
ISSN :: 24055794
Volume :: 27
Issue :: 1
Database :: Supplemental Index
Journal :: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Publication Type :: Periodical
Accession number :: ejs58752977
Full Text :: https://doi.org/10.1016/j.jctube.2022.100299

Full Text Access

Tools